VBY-825

VBY-825 is an orally available novel reversible cathepsin inhibitor that has high inhibitory potency against cathepsin B, L, S and V, and possesses anti-tumor, anti-inflammatory and analgesic effects[1][2][3].

Product Specifications

CAS Number

[1310340-58-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Cathepsin

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/VBY-825.html

Purity

99.81

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

CC[C@H](NC([C@@H](N[C@@H](C1=CC=C(F)C=C1)C(F)(F)F)CS(=O)(CC2CC2)=O)=O)C(C(NC3CC3)=O)=O

Molecular Formula

C23H29F4N3O5S

Molecular Weight

535.55

Precautions

H302, H315, H319, H335

References & Citations

[1]Elie BT, et al. Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie. 2010 Nov;92 (11) :1618-24.|[2]Umaretiya, et al. Cathepsin Inhibitor, VBY-825, Attenuates Bone Cancer Induced Pain in Mice. The University of Arizona. |[3]Laura Orellano, et al. Therapeutic potential of VBY-825 in MSU crystal-induced NLRP3 inflammasome activation. The Journal of Immunology. 2024. 212 (1_Supplement) : 0957_5533.